Sale

Intravenous Immunoglobulin Market

Global Intravenous Immunoglobulin Market Size, Share, Growth, Trends, Forecast: By Type; By Applications: Hypogammaglobulinemia, CIDP, Immunodeficiency Diseases, Congenital AIDS, Others; By Route of Administration; By End User; By Distribution Channel; Regional Analysis; Patent Analysis; Supplier Landscape; 2024-2032

Global Intravenous Immunoglobulin Market Outlook 

The global intravenous immunoglobulin market is expected to grow at a CAGR of 6.90% between 2024 and 2032. The market is being driven by increasing prevalence of immunodeficiency diseases and rising adoption of intravenous immunoglobulin treatments.  

 

intravenous immunoglobulin market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Key Trends in the Market 

Intravenous immunoglobulin or IVIG is a therapy treatment targeted towards patients deficient of antibodies that would otherwise fight infections or are suffering from autoimmune diseases. Immunoglobulins are prepared by the immune system of people who are healthy and have sufficient antibodies. IVIG treatment response varies from person to person, and there is a likelihood that some patients may not respond to the treatment.

 

  • A wide number of conditions can be treated with IVIG therapy. The increasing adoption rate for the intravenous immunoglobulin therapy because of the safety and efficacy it provides is expected to drive the growth of the intravenous immunoglobulin market.
  • COVID-19 has impacted the health of the people and weakening the immune systems of many worldwide. Intravenous immunoglobulin therapy treatment can prove effective in such cases, by boosting the weakened immune systems.
  • Intravenous immunoglobulin therapy may be cost prohibitive as it is a long-term therapy with costs varying depending upon the severity of the original condition. Lowering costs are a key trend for the global market for intravenous immunoglobulin that can support its long term growth.
  • Geriatric populations are also likely to have weakened immune systems, increasing their susceptibility to other illnesses. IVIG treatment can help improve the health of such populations, increasing their overall lifespan.

 

Market Analysis 

 

intravenous immunoglobulin market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on form, the intravenous immunoglobulin market can be bifurcated into liquid and lyophilised. On the basis of product the market can be divided into IGG, IGA, IGM, IGE, and IGD. Based on indication, the market is segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), idiopathic thrombocytopenic purpura (ITP),  Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, and chronic lymphocytic leukaemia, among others. 

 

By distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and others. Based on end use the market is divided into hospitals, clinics, and home care. The regional markets can be categorised into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.  

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global intravenous immunoglobulin market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.  

 

  • CSL Limited
  • Grifols, S.A.
  • Octapharma AG
  • Shanghai RAAS Blood Products Co., Ltd.
  • Biotest AG
  • LFB S.A
  • Others

 

Market Share by Form

The liquid form segment of the intravenous immunoglobulin market accounts for a substantial share, due to the ease of administering liquids intravenously, without concerns of mixing powders in required concentrations. Liquid immunoglobulin is collected from the blood plasma of the individuals only after screening them and making sure that they are healthy. The blood plasma collected is purified and is tested for serious infections such as AIDS and hepatitis. 

 

Lyophilised or powder form of intravenous immunoglobulin is administered within 2-3 hours of its dissolution. It offers greater flexibility in changing dosages for patients new to the treatment and trying out various concentrations to find an ideal match. 

 

Market Share by End Use

Intravenous immunoglobulin is typically given to patients in hospitals or clinics but in some cases it can be administrated through home care, under careful supervision of a professional nurse. As IVIG treatment tends to be long-term, many patients start out with treatments in hospitals or clinics, and later moving on to home care. 

 

Administration of intravenous immunoglobin through home care is preferable for long-term treatment as it is more comfortable for patients to receive treatment in the comfort of their own home, due to which growth of the home care segment in the intravenous immunoglobulin market is expected. Depending upon the region and insurance coverage, home care may or may not be more expensive than receiving intravenous immunoglobin in hospitals or clinics. 

 

intravenous immunoglobulin market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape 

CSL Limited founded in 1916 has its headquarter in Melbourne, Australia. This biotechnology company mainly focusses on innovating medical solutions to treat bleeding disorders, neurological disorders, and other disorders or medical problems. 

 

Grifols, S.A. was established in 1940 and has its headquarter in Barcelona, Spain. It is a pharmaceutical and chemical manufacturer known for the development of blood-plasma based products. It also supplies reagents, devices, and instruments for laboratories involved in clinical testing.

 

Octapharma AG was incorporated in 1983 and has its headquarter in Lachen, Switzerland. It is a family owned company and develops human proteins from human cell lines and plasma. They typically manufacture products that treat bleeding disorders and other rare diseases. 

 

Other market players include Shanghai RAAS Blood Products Co., Ltd., Biotest AG, and LFB S.A, among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Applications
  • Route of Administration
  • End User
  • Distribution Channel
  • Region
Breakup by Type
  • IgG
  • IgM
  • IgA
  • IgE
  • IgD
Breakup by Applications
  • Hypogammaglobulinemia
  • CIDP
  • Immunodeficiency Diseases
  • Congenital AIDS
  • Chronic Lymphocytic Leukemia
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • ITP
  • Kawasaki Disease
  • Guillain-Barre syndrome
  • Others
Breakup by Route of Administration
  • Intravenous
  • Subcutaneous
Breakup by End User
  • Clinics
  • Hospitals
  • Specialty Clinics
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Baxter
  • Bayer AG
  • Merck & Co., Inc.
  • Biotest AG
  • Top Bio Group Co., Ltd.
  • CSL Limited
  • Octapharma AG
  • Grifols, S.A.
  • Kedrion S.p.A
  • Shanghai RAAS Blood Products Co., Ltd.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Intravenous Immunoglobulin Market Overview 

    3.1    Global Intravenous Immunoglobulin Market Historical Value (2017-2023) 
    3.2    Global Intravenous Immunoglobulin Market Forecast Value (2024-2032)
4    Global Intravenous Immunoglobulin Market Landscape
    4.1    Global Intravenous Immunoglobulin Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Intravenous Immunoglobulin Product Landscape
        4.2.1    Analysis by Type
        4.2.2    Analysis by Applications
        4.2.3    Analysis by End User
5    Global Intravenous Immunoglobulin Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Intravenous Immunoglobulin Market Segmentation 
    6.1    Global Intravenous Immunoglobulin Market by Type
        6.1.1    Market Overview
        6.1.2    IgG
        6.1.3    IgM
        6.1.4    IgA
        6.1.5    IgE
        6.1.6    IgD
    6.2    Global Intravenous Immunoglobulin Market by Applications
        6.2.1    Market Overview
        6.2.2    Hypogammaglobulinemia
        6.2.3    CIDP
        6.2.4    Immunodeficiency Diseases
        6.2.5    Congenital AIDS
        6.2.6    Chronic Lymphocytic Leukemia
        6.2.7    Myasthenia Gravis
        6.2.8    Multifocal Motor Neuropathy
        6.2.9    ITP
        6.2.10    Kawasaki Disease
        6.2.11    Guillain-Barre syndrome
        6.2.12    Others
    6.3    Global Intravenous Immunoglobulin Market by Route of Administration
        6.3.1    Market Overview
        6.3.2    Intravenous
        6.3.3    Subcutaneous
    6.4    Global Intravenous Immunoglobulin Market by End User
        6.4.1    Market Overview
        6.4.2    Clinics
        6.4.3    Hospitals
        6.4.4    Specialty Clinics
        6.4.5    Others
    6.5    Global Intravenous Immunoglobulin Market by Distribution Channel
        6.5.1    Market Overview
        6.5.2    Hospital Pharmacy
        6.5.3    Retail Pharmacy
        6.5.4    Online Pharmacies
        6.5.5    Others
    6.6    Global Intravenous Immunoglobulin Market by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Intravenous Immunoglobulin Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Intravenous Immunoglobulin Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Intravenous Immunoglobulin Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Intravenous Immunoglobulin Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Intravenous Immunoglobulin Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Baxter
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    Bayer AG
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Merck & Co., Inc.
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Biotest AG
        17.4.1    Financial Analysis
        17.4.2    Product Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Top Bio Group Co., Ltd.
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    CSL Limited
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Octapharma AG
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Grifols, S.A.
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Kedrion S.p.A
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10    Shanghai RAAS Blood Products Co., Ltd.
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
18    Global Intravenous Immunoglobulin Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market is expected to grow at a CAGR of 6.90% between 2024 and 2032.

The major market drivers are increasing prevalence of auto immune diseases, growing geriatric population, and technological advancements in intravenous immunoglobulin therapies.

The market is segmented based on form, product, indication, distribution channels, end use, and region.

Key trends of the market are increasing use of intravenous immunoglobulin therapies for multiple conditions, home care options for long-term and mor comfortable care, and research into methods of lowering costs of the therapy.

The regional markets can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.

Key distribution channels of the market are hospital pharmacies, retail pharmacies, and others.

Key players in the global intravenous immunoglobulin market are CSL Limited, Grifols, S.A., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., Biotest AG, and LFB S.A, among others.

Intravenous immunoglobulin, also abbreviated as IVIG, is a therapy treatment for people who are deficient of antibodies and have weak immune systems.

Immunoglobulins are prepared from samples donated by people who have immune systems that are healthy with sufficient antibodies.

IVIG response varies from person to person, and some may not even respond to the treatment. Typically, the treatment is long-term.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER